Journal list menu
Author Guidelines
NIH Public Access Mandate
For those interested in the Wiley policy on the NIH Public Access Mandate, please visit our policy statement
For additional tools visit Author Resources - an enhanced suite of online tools for Wiley InterScience journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.
Author Guidelines
Manuscript Submission
New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/GCC. Should your manuscript proceed to the revision stage, you will be directed to make your revisions via the same submission portal. You may check the status of your submission at anytime by logging on to submission.wiley.com and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].
Pre-submission enquiries can be sent to the GCC Editorial Office ([email protected]).
All manuscripts submitted to Genes, Chromosomes & Cancer must be submitted solely to this journal and may not have been published in another publication of any type, professional or lay. Upon acceptance of a manuscript for publication, the author will be requested to sign an agreement transferring copyright to the publisher, who reserves copyright. No published material may be reproduced or published elsewhere without the written permission of the publisher and the author. The Journal will not be responsible for the loss of manuscripts at any time. All statements in, or omissions from, published manuscripts are the responsibility of the authors, who will assist the editorial office by reviewing proofs before publication. Reprint order forms will be sent with the proofs.
Free Format Submission
Genes, Chromosomes, and Cancer now offers free format submission for a simplified and streamlined submission process. Before you submit, you will need:- Your Manuscript: this should be an editable file including text, figures, and tables, or separate files - whichever you prefer. All required sections should be contained in your manuscript, including abstract (which does not need to be correctly styled), introduction, materials and methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. If the figures are not of sufficiently high quality, your manuscript may be delayed. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of the English language is poor.
- An Orcid ID, freely available at https://orcid.org.
- The title page of the manuscript, including:
- Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):
- Data availability statement
- Funding statement
- Conflict of interest disclosure
- Ethics approval statement
- Patient consent statement
- Permission to reproduce material from other sources
- Clinical trial registation; Important: the journal operates as a double-blind peer review policy. Please anonymise your manuscript and supply a separate title page file. To submit login at https://wiley.atyponrex.com/journal/GCC and create a new submission. Follow the submission steps as required and submit the manuscript.
By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
Manuscript Preparation
Review Articles review a specific field through an appropriate literature survey. An Abstract is required. Materials and Methods and Results sections are not required. Although there are no restrictions on the number of pages or figures, the Review should be as concise as possible. Review articles are usually invited; the editors welcome proposals and suggestions for topics.
Research Articles should report original data and contain sections in the following order: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments (optional), References, Tables, and Figure Legends. Use generic names of drugs and give manufacturer, city, and state or country of all trademarked equipment mentioned in the text.
Brief Reports documenting either experimental results or informative clinical observations should convey a specific key message with definitive supporting evidence and have immediate impact. They are not intended for the publication of incomplete or preliminary results. Single case reports, purely diagnostic, prognostic or predictive biomarker studies will not be considered unless they elucidate novel and important aspects on disease biology or new approaches to therapy. Brief Reports should be formatted as Regular Articles with all appropriate section headings, but may not exceed 2,500 words, two figures/tables and 25 references. An abstract is required.
Letters to the Editors comment on a work recently published in the journal. These should be kept brief, in general not longer than one printed page, but may be illustrated. No abstract is required. Authors of the work commented on will be invited to reply in the same issue of the Journal.
Perspective Articles are intended to shed light on general topics in cancer genetics in a manner different from that normally found in Research Articles and Review Articles. They should be provocative and juxtapose lines of reasoning that are conventionally seen as separate, to achieve a deeper understanding of the problems discussed. Perspective Articles are usually invited; the editors welcome proposals and suggestions for topics. An abstract is required.
Format of Manuscript Elements
Title Page. Give a descriptive title with no abbreviations. Provide first and last names of each author and department and institutional affiliations. Give full address of corresponding author and telephone, telex, and FAX numbers and an abbreviated title not to exceed 45 characters. Avoid nonstandard abbreviations; do not abbreviate single words (see "Conventions and Nomenclature").
Abstract. Abstrract structured (intro/methods/results/conclusion) or unstructured. Limit the abstract to a single paragraph of not more that 250 words. It must describe work and include purpose, brief statement of methods, and results. Literature references should not be given in the Abstract. Definitions of abbreviations (see "Conventions and Nomenclature") must be repeated when the abbreviation is used for the first time in the text.
Main Body. Formatted as introduction, materials & methods, results, discussion, conclusion
Key Words and Search Engine Optimization. Driving usage and readership is critically important to raising the visibility of your published research. One of the key factors in sustaining long-term usage is through search engine optimization (SEO). Below is a list of suggested ways of maximizing your SEO.
1. Make sure your article title is SEO-friendly. It should be descriptive, and it must include a key phrase from your topic. Key words should appear within the title's first 65 characters.
2. Provide up to seven key words or phrases in the keyword field.
3. Be sure your key words and phrases appear in your abstract several times, but don't go overboard or the search engine may kick you out.
4. When referencing authors, be consistent. Use their names as they generally appear in past online publications.
5. When appropriate, use your key words in article section headings.
Remember: They can't read it if they can't find it!
For more detailed information on SEO, including helpful examples, go to http://authorservices.wiley.com/bauthor/seo.asp
Materials and Methods. Experimental procedures should be described in sufficient detail to enable the work to be repeated. References to other papers describing the techniques may be given. Correct chemical names should be given and strains of organisms, clones, etc. should be specified. The names and addresses for suppliers of uncommon reagents or instruments should be mentioned. Authors should draw attention to any particular chemical or biological hazards that may be involved in carrying out the experiments described. Any relevant safety precautions should be described; if an accepted code of practice has been followed, a reference to the relevant standards should be given.
References. Journal follows AMA reference style.
Book:
1. Adkinson N, Yunginger J, Busse W, Bochner B, Holgate S, Middleton F, eds. Middleton’s Allergy: Principles and Practice. 6th ed. St Louis, MO: Mosby; 2003.
2. US Department of Health and Human Services. Understanding and Improving Health and Objectives for Improving Health. Vol 1. 2nd ed. Washington, DC: US Dept of Health and Human Services; 2000.
3. Green M, ed. Bright Futures: National Guidelines for Health Supervision of Infants, Children, and Adolescents. 2nd rev ed. Arlington, VA: national Center for Education in Maternal and child Health; 2002.
Chapter in a book:
4. Solensky R. Drug allergy: desensitization and treatment of reactions to antibiotics and aspirin. In: Lockey P, ed. Allergens and Allergen Immunotherapy. 3rd ed. New York, NY: Marcel Dekker; 2004:585-606.
Book as a part of a series:
5. Brune K, Handwerker HO, eds. Hyperalgesia: Molecular Mechanisms and Clinical Implications. Seattle, WA: IASP Press; 2004. Progress in Pain Research and Management; vol 30.
Journal:
6. Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol. 2004;61(7):1025-1029.
7. Keppel K, Pamuk E, Lynch J, et al. Methodologic issues in measuring health disparities. Vital Health Stat 2. 2005;(141):1-16.
8. Crino L, Cappuzzo F. Present and future treatment of advanced mom-small-cell lung cancer. Semin Oncol. 2002;29(3)(suppl 9):9-16.
9. McCormick MC, Kass B, Elixhauser A, Thompson J, Simpson L. Annual report on access to and utilization of health care for children and youth in the United States: 1999. Pediatrics. 2000;105(1, pt 3):219-230.
Newspaper:
10. Goode E. Study finds jump in children taking psychiatric drugs. New York Times. January 14, 2003:A21.
Thesis/dissertation:
11. Underman C. Fully Automatic Segmentation of MRI Brain Images Using Probabilistic Diffusion and a Watershed Scale-Space Approach [master’s thesis]. Stockholm, Sweden: NADA, Royal Institute of Technology; 2001.
Package Inserts:
12. Cialis [package insert]. Indianapolis, IN: Eli Lilly & Co; 2003.
Patent:
13. Guiliano K, Kapur R, inventors; Cellomics Inc, assignee. System for cell-based screening. US patent 6,875,578. April 5, 2005.
Web sites:
14. International Society for Infectious Diseases. ProMED-mail Web site. http://www.promedmail.org. Accessed December 6, 2005.
Symposium/proceedings:
15. Weber KJ, Lee J, Decresce R, Subhasis M, Prinz R. Intraoperative PTH monitoring in parathyroid hyperplasia requires stricter criteria for success. Paper presented at: 25th Annual American Association of Endocrine Surgeons meeting; April 6, 2004; Charlottesville, VA.
16. Khuri FR, Lee JJ, Lippman Sm, et al. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. In: Proceedings from the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, IL. Abstract 359.
17. Ofri D. Incidental Findings: Lessons from My patients in the Art of medicine. Boston, MA: Beacon Press. In Press.
Tables. All tables must be cited in the text and have titles. Number them consecutively with arabic numerals. Cite each table at the most appropriate point in the text. Tables should present comparisons of data that are too cumbersome to describe in the text; they should not merely repeat text information. Each table should be typed double-spaced on a separate sheet of paper and should include a title and, in a footnote, definitions of all abbreviations used in it (even if abbreviations are defined in the text), indicated by lowercase superscript letters, a, b, c, etc.
Figures. Figures should be numbered in one consecutive series using arabic numerals, and keyed into the text. All original letters, numbers, and symbols must be large enough that, when reduced to journal format (8 1/4 x 11 inch double-column), they will remain at least 2mm high. Each figure requires a corresponding legend; legends should be double-spaced and grouped on a separate page(s). Each legend should describe briefly the information presented; detailed descriptions of procedures should appear in the Materials and Methods section. Abbreviations used in figures and photographs must match exactly those used in the text.
Rapid Inspector TM gives authors of scientific, technical, and medical journals a resource for certifying their illustrations prior to submission. Utilizing this software will ensure that your graphics are suitable for print production. To download this journal's free Rapid Inspector software, please visit http://rapidinspector.cadmus.com/wi .
Conventions and Nomenclature. In the description of karyotypes, authors should follow the most recent recommendations of the International Standing Committee on Human Cytogenetic Nomenclature (ISCN). For gene mapping nomenclature, the most recent guidelines of the Human Gene Mapping Nomenclature Committee should be used. Authors should use SI units and follow the guidelines for abbreviations and symbols of the IUPAC-IUB Joint Commission on Biochemical Nomenclature. See Eur J Biochem (1970) 15:203-208; corrected (1972) 25:1-4. For bases in nucleic acid sequences, see Eur J Biochem (1985) 150:1-5. All nonstandard abbreviations used in the text should be defined when first used.
Submission of Data to the Genetics Databases. The editorial policy of the journal is to encourage the use of genetics databases (e.g., HGML, GenBank, EMBL) as repositories for detailed DNA sequences and mapping assignments, etc. Authors are encouraged to complete data entry and annotation forms for the appropriate databases, which can be obtained from the databases. Include copies of these summaries and database entries/accession information with the manuscripts at the time of submission. Where possible, published articles will be accompanied by footnotes with accession information for retrieving and cross-referencing data from the genetic information repositories.
OPEN ACCESS IN HYBRID JOURNALS
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement
If the open access in hybrid titles option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp
For authors choosing open access in hybrid titles
If the open access in hybrid titles option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If you select the open access in hybrid titles option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.
For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:
Creative Commons Attribution License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
Data Sharing and Data Accessibility
Please review Wiley’s policy here. This journal expects data sharing.
Refer and Transfer Program
Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program. If your manuscript is not accepted, you may receive a recommendation to transfer your manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant.
Expects Data Sharing
Genes, Chromosomes & Cancer recognizes the many benefits of archiving research data. Genes, Chromosomes & Cancer expects you to archive all the data from which your published results are derived in a public repository. The repository that you choose should offer you guaranteed preservation (see the registry of research data repositories at https://www.re3data.org/) and should help you make it findable, accessible, interoperable, and re-useable, according to FAIR Data Principles (https://www.force11.org/group/fairgroup/fairprinciples).
All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. If you cannot share the data described in your manuscript, for example for legal or ethical reasons, or do not intend to share the data then you must provide the appropriate data availability statement. Genes, Chromosomes & Cancer notes that FAIR data sharing allows for access to shared data under restrictions (e.g., to protect confidential or proprietary information) but notes that the FAIR principles encourage you to share data in ways that are as open as possible (but that can be as closed as necessary).
Sample statements are available here. If published, all statements will be placed in the heading of your manuscript.
Wiley’s Author Name Change Policy
In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.
Production Editor
E-mail:[email protected]